IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dinesh O. Shah, et al.

Serial No.: 09/891,983

Filed: June 26, 2001

For: METHODS FOR THE

SIMULTANEOUS DETECTION OF HCV ANTIGENS AND HCV ANTIBODIES

Attorney Docket No.: 6821.US.01

Examiner: (not yet assigned)

Group Art Unit: 1645

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:

U.S. Patent and Trademark Office Box Sequence

P.O. Box 2327

Arlington, VA 22202

Date of Depositr

Kimberly A. Iorio

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, VA 22202

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amio Acid Sequence Disclosures, dated March 26, 2002, in the patent application identified above, Applicants submit herewith a substitute Sequence Listing in computer readable form. For the Examiner's convenience, a paper copy of the Sequence Listing is also included herewith.

The Commissioner is hereby authorized to charge the payment of any patent application processing fees under 37 CFR 1.17 concerning this transaction, or to credit any overpayment to Deposit Account No. 01-0025. A duplicate copy of this sheet is attached.

ABBOTT LABORATORIES

Telephone: (847) 938-7576 Facsimile: (847) 938-2623 Respectfully submitted, P. Mukerji, et al.

Cheryl L. Becker

Registration No. 35,441 Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicants: Dinesh O. Shah, et al.

Serial No.: 09/891,983

Filed: June 26, 2001

For: METHODS FOR THE

SIMULTANEOUS DETECTION OF HCV ANTIGENS AND HCV ANTIBODIES

Attorney Docket No.: 6821.US.01

Examiner: (not yet assigned)

Group Art Unit: 1645

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:

U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, VA 22202

Daile of Deposit:

Sumberly (). Isro 4-16-02

Kimberly A. Korjo

TRANSMITTAL LETTER

U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, VA 22202

Dear Sir:

Enclosed herewith for the patent application identified above entitled METHODS FOR THE SIMULTANEOUS DETECTION OF HCV ANTIGENS AND HCV ANTIBODIES are the following:

- 1. Response to Notice to Comply (1 Page), in duplicate;
- 2. Copy of Notice to Comply (1 Page);
- 3. Substitute Paper Copy of the Sequence Listing (9 Pages);
- 4. Substitute Computer Readable Form Copy (1 Diskette);
- 5. Statement to Support Filings and Submissions in Accordance with 37 CFR §§1.821-1.825 (1 Page);
- 6. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES Telephone: (847) 938-7576

Facsimile: (847) 938-2623

Respectfully submitted, Dinesh O. Shah, et al.

Cheryl L. Becker
Registration No. 35,441
Attorney for Applicants





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/891,983

Filed: June 26, 2001

For: METHODS FOR THE SIMULTANEOUS DETECTION OF HCV ANTIGENS AND HCV

ANTIBODIES

Attorney Docket No.: 6821.US.01

Examiner: (not yet assigned)

Group Art Unit: 1645

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as

follows:

U.S. Patent and Trademark Office

Box Sequence P.O. Box 2327 Arlington, VA 22202

Date of Deposit:

Kimberly A. Iorio

STATEMENT TO SUPPORT THE FILINGS AND SUBMISSIONS IN ACCORDANCE WITH 37 CFR §§1.821-1.825

U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, VA 22202

Dear Sir:

The undersigned, being the attorney of record of the above-identified patent application, submits the following statement regarding the substitute Sequence Listing in paper and computer readable form, both of which are filed herewith:

I hereby state that the content of the substitute paper and computer readable form copies of the Sequence Listing are identical and that they contain no sequence information that would constitute new matter beyond the originally filed application.

Also, it is respectfully requested that the computer readable form and paper copy of the Sequence Listing, filed herewith, be entered into the case file and replace the previously filed computer readable form and paper copy of the Sequence Listing.

23492

ABBOTT LABORATORIES Telephone: (847) 938-7576 Facsimile: (847) 938-2623 Respectfully submitted, Dinesh O. Shah, et al.

Cheryl L. Beoker Registration No. 35,441 Attorney for Applicants

www.uspto.gov



ĨÜ

Ü

U

ij

22

ſIJ

TU



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS

UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER

09/891,983 06/26/2001 Dinesh O. Shah

6821.US.O1

CONFIRMATION NO. 9651

FORMALITIES LETTER

OC000000007720841

Steven F. Weinstock ABBOTT LABORATORIES D-377/AP6D-2 100 Abbott Park Road Abbott Park, IL 60064-3500

Date Mailed: 03/26/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customel Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER 09/891,983 Dinesh O. Shah

06/26/2001

6821.US.O1

Steven F. Weinstock **Abbott Laboratories** Department 377 / AP6D-2 100 Abbott Park Road Abbott Park, IL 60064-6050



CONFIRMATION NO. 9651 FORMALITIES LETTER

OC000000006500882

Date Mailed: 08/31/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

10025 09891983 09891983 09891983

130.00 CH '920, 00-CH

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below. however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also



provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE